drugset
drugset / Trial / NCT07143864

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

NCT07143864 ↗

Not yet recruiting 40 enrolled First Affiliated Hospital of Chongqing Medical University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Timeline

Start
2025-09-15
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody — —

Indications

primary cutaneous amyloidosis